Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
CTNM vs IMMX — Stock Comparison
Compare CTNM and IMMX side-by-side on StoQuant: CTNM Q-Score 39 vs IMMX 58; analyst signal 81 vs 77. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- CTNM — Contineum Therapeutics, Inc. Class A Common Stock · Health Care · market cap $274M · Q-Score verdict Sell (39.0, grade D) · analyst signal 81/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 91/100, analyst consensus 90/100 · weakest signals: valuation 65/100, technicals 10/100. Full CTNM research.
- IMMX — Immix Biopharma, Inc. · Health Care · market cap $676M · Q-Score verdict Buy (58.0, grade B) · analyst signal 77/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 88/100, analyst consensus 81/100 · weakest signals: technicals 62/100. Full IMMX research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: CTNM research · IMMX research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.